WHITEHOUSE STATION, N.J. (AP) – Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments.
The Food and Drug Administration said it has granted accelerated approval to Merck’s Keytruda, for treating melanoma that’s spread or can’t be surgically removed, in patients previously treated with another cancer drug.
The genetically engineered drug, known chemically as pembrolizumab, is part of a hot, promising new class of antibody-based drugs. They work by taking a brake off the immune system so it can better recognize and attack cancer cells.
“Ninety percent of patients have basically no side effects,” Dr. Antoni Ribas, a UCLA researcher who was the lead investigator of a crucial study of Keytruda, told The Associated Press in an interview.
By comparison, most patients getting chemotherapy suffer with nausea, vomiting and hair loss.
